Primary Prevention of Cardiovascular Events with Low Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial

Diabetes Care

Volumn 26, Issue 12, 2003, Pages 3264-3272

  Sacco, Michele ^a   Pellegrini, Fabio ^a   Roncaglioni, Maria C ^a   Avanzini, Fausto ^a   Tognoni, Gianni ^a   Nicolucci, Antonio ^a  

^a Ist di Ric Farmacol Mario Negri ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENERAL PRACTITIONER; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT MONITORING; PREMATURITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ASPIRIN; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OBESITY; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SAFETY; SMOKING; VITAMIN E;

EID: 0345411332     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.12.3264     Document Type: Article

References (27)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
2. Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 342:1040-1042, 2000
3. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM: Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care 15:1156-1167, 1992
4. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
5. Ceriello A, Bortolotti N, Falleti E, Taboga C, Tonutti L, Crescentini A, Motz E, Lizzio S, Russo A, Bartoli E: Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 20:194-197, 1997
6. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafrier B, Thompson E, Norton S, Gilliland J, Dou R: Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 296:313-316, 1988
7. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the on-going Physicians' Health Study. N Engl J Med 321:129-135, 1989
8. The Medical Research Council's General Practice Research Framework: Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233-241, 1998
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
10. Collaborative Group of the Primary Prevention Project (PPP): Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. tice. Lancet 357:89-95, 2001.
11. Hayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136:161-172, 2002
12. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
13. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360:23-33, 2002
14. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25:1919-1927, 2002
15. The Heart Outcomes Prevention Evaluation Study Investigators: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342:154-160, 2000
16. Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 136:157-160, 2002
17. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S87-S88, 2003
18. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy. Study report 14. JAMA 268:1292-1300, 1992
19. Halushka MK, Halushka PV: Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105:1620-1622, 2002
20. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S: Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 46:2096-2101, 1997
21. Albertini JP, Valensi P, Lonneau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L: Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: effect of intensive insulin treatment. Diabetes Care 21:1008-1013, 1998
22. Ceriello A, Motz E: Prevention of vascular events in diabetes mellitus: which "anti-thrombotic" therapy? (Comment). Diabetologia 39:1405-1406, 1996
23. Meade TW, Brennan PJ: Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321:13-17, 2000
24. Friend M, Vucenik I, Miller M: Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326:82-83, 2003
25. Di Minno G, Silver MJ, Cerbone AM, Murphy S: Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886-891, 1986
26. Lauer MS: Clinical practice: aspirin for primary prevention of coronary events. N Engl J Med 346:1468-1474, 2002
27. Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen ZM, Collins R, Flather M, Franzosi MG, Kjekshus J, Kober L, Liu LS, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S, Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group: Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of ifidividual data from 96,712 randomized patients. J Am Coll Cardiol 35:1801-1807, 2000